View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 24, 2019updated 23 Dec 2019 10:27am

UK researchers test virtual reality technology to detect Alzheimer’s

Researchers at the University of Cambridge in the UK have found that virtual reality (VR) could detect early Alzheimer’s disease more accurately compared to existing ‘gold standard’ cognitive tests.

Researchers at the University of Cambridge in the UK have found that virtual reality (VR) could detect early Alzheimer’s disease more accurately compared to existing ‘gold standard’ cognitive tests.

Existing pen-and-paper cognitive tests are not designed to evaluate patients for navigation difficulties, which occur because of damage to the entorhinal cortex region of the brain.

To address this, a team from the university’s department of clinical neurosciences worked with Professor Neil Burgess at University College London (UCL) to create and assess a VR navigation test in patients who are at risk of dementia.

The test involves use of a VR headset to take a navigation test while walking within a simulated environment.

Since successful completion of the task requires intact the entorhinal cortex functioning, patients with early Alzheimer’s disease are believed to be disproportionately affected on the test.

In 45 patients with mild cognitive impairment (MCI), the team obtained cerebrospinal fluid (CSF) samples and analysed for biomarkers of underlying Alzheimer’s. Of the total participants, 12 tested positive.

The study also involved 41 age-matched healthy controls for comparison. All MCI patients showed worse performance on the navigation task than the healthy controls.

In addition, MCI patients with positive CSF markers were observed to perform worse than those with negative markers.

“A VR test of navigation may be better at identifying early Alzheimer’s disease than tests we use at present in clinic and in research studies.”

The researchers also found that the VR navigation task was better at distinguishing low and high risk MCI patients than currently-used gold standard tests to diagnose early Alzheimer’s.

University of Cambridge clinical neurosciences department scientist Dr Dennis Chan said: “These results suggest a VR test of navigation may be better at identifying early Alzheimer’s disease than tests we use at present in clinic and in research studies.”

Findings from the study have been published in the Brain journal.

The researchers believe that VR could also help clinical trials of drugs intended to slow down, or halt Alzheimer’s progression.

In addition, Dr Chan formed alliances to develop apps to detect the disease and monitor its progression.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network